IBS involves dysregulated gut motility, visceral hypersensitivity, intestinal barrier dysfunction, and gut-brain axis dysregulation — producing bloating, cramping, altered bowel habits, and abdominal pain without structural pathology. Peptide research targets the motility, barrier, and neurological components that conventional treatment rarely addresses simultaneously.
1. BPC-157 — Gut Motility / Barrier Repair
BPC-157 normalizes gut motility in both constipation-dominant and diarrhea-dominant IBS by modulating enteric nervous system function and reducing mucosal inflammation. It repairs tight junction integrity (reducing the visceral hypersensitivity that comes with leaky gut) and protects the mucosa from the stress-induced damage that triggers IBS flares.
Dosing Protocol: 500 mcg oral BPC-157 (arginate form) daily, taken fasted. Stack with 250 mcg SubQ for combined systemic effects. Cycle: 8–12 weeks.
2. KPV — Mucosal Anti-Inflammatory
Mucosal micro-inflammation — invisible on colonoscopy but present in IBS biopsies — contributes to visceral hypersensitivity and motility dysfunction. KPV reduces this subclinical mucosal inflammatory tone, improving the sensory threshold in the gut and reducing the mast cell activation that drives IBS symptom severity.
Dosing Protocol: 200–500 mcg oral daily (capsule for intestinal targeting). Cycle: 6–8 weeks.
3. VIP — Enteric Nervous System Regulation
VIP is a critical neurotransmitter in the enteric nervous system (the gut’s own nervous system), regulating smooth muscle relaxation, secretion, and pain signal modulation. In IBS, VIP signaling is dysregulated. Supplemental VIP normalizes gut motility patterns and reduces visceral pain sensitivity through enteric receptor activation.
Dosing Protocol: 25–50 mcg SubQ daily. Intranasal may access gut via vagal-enteric pathways. Cycle: 4–6 weeks.
4. Semax — Gut-Brain Axis / Stress-IBS Connection
IBS is strongly driven by the gut-brain axis — stress activates the HPA axis, which directly worsens gut motility and visceral sensitivity. Semax modulates HPA axis reactivity, reduces cortisol-driven gut dysfunction, and improves the CNS processing of visceral pain signals, addressing the neural component of IBS that is often the primary driver.
Dosing Protocol: 100–300 mcg intranasal daily. SubQ: 200–400 mcg daily. Cycle: 10 days on / 5 days off.
BPC-157 forms the physical gut repair foundation — healing the barrier and normalizing motility. KPV quiets the micro-inflammation sensitizing the gut to pain and dysfunction. VIP restores the enteric neuropeptide regulation that controls smooth muscle behavior. Semax addresses the CNS stress-gut axis that triggers and maintains IBS flares, closing the loop on a condition that is as much neurological as gastrointestinal.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).